Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Euvax B
- Development stage
- Approved
- Lead developer
- LG Chem
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Euvax B is a recombinant hepatitis B vaccine consisting of purified hepatitis B surface antigen (HBsAg). The antigen is produced using recombinant DNA technology in yeast cells (*Saccharomyces cerevisiae*) and is adsorbed onto an aluminum hydroxide adjuvant to enhance immunogenicity. Originally developed by LG Life Sciences in 1991 and distributed globally by Sanofi Pasteur, the vaccine is indicated for active immunization against infection caused by all known subtypes of the hepatitis B virus. It was the first Korean hepatitis B vaccine to receive WHO prequalification (1996) and has been registered in over 60 countries. In clinical research, it is frequently used as a challenge dose to evaluate long-term immune memory in children previously primed with hexavalent vaccines such as Hexaxim or Infanrix hexa.
- Brand names
- Euvax B
- Other names
- Hepatitis B vaccine (recombinant)LG Hepatitis B Vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on Euvax B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Euvax B.